Dr. Margaret M. Wasilewski, is board certified in Infectious Diseases and Internal Medicine and completed Infectious Diseases and Clinical Pharmacology fellowships at the University of California, San Francisco. Dr. Wasilewski has nine years clinical development experience including seven years at Eli Lilly and Company where she worked as clinical team leader for the Oritavancin registration project.
She has experience in all stages of drug development with specialty in the in antibacterial, antivirals, and sepsis. Her expertise includes clinical strategy, clinical and regulatory plan development and implementation, dose-finding solutions, Phase II/III drug development protocol development, risk assessment, safety and efficacy evaluation, due diligence, final study report completion, and manuscript strategy and development. In addition, she has experience in business development, partnering with small pharmaceuticals and contract research organizations.